Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines
Friday, 29 March 2024
Authored Items
Can Some Patients with Multiple Sclerosis Stop Treatment?
Caroline Helwick
Web Exclusives
in
Multiple Sclerosis
Oral Ozanimod: A Safer Sphingosine-1-Phosphate Receptor Modulator?
Caroline Helwick
Web Exclusives
in
Multiple Sclerosis
Vitamin D Supplementation Shows Benefits in Multiple Sclerosis, but Questions Remain
Caroline Helwick
Web Exclusives
in
Multiple Sclerosis
Ocrelizumab Receives Breakthrough Therapy for Progressive Multiple Sclerosis
Caroline Helwick
VBCN - April 2016 Volume 3, No 1
in
Multiple Sclerosis
Ozanimod Achieves Very Low Relapse Rate in MS
Caroline Helwick
VBCN - April 2016 Volume 3, No 1
in
Multiple Sclerosis
Stem-Cell Transplantation Shows Promise in Multiple Sclerosis, but Major Concerns Remain
Caroline Helwick
VBCN - April 2016 Volume 3, No 1
in
Multiple Sclerosis
Treatment of Psoriatic Arthritis Explored by Cost-Effectiveness
Caroline Helwick
VBCR - June 2015, Volume 4, No 3
in
Psoriatic Arthritis
Treatment Outcomes and Cost Assessed for Systemic Lupus Erythematosus
Caroline Helwick
VBCR - June 2015, Volume 4, No 3
in
Lupus
Ankylosing Spondylitis Treatment Costs Assessed
Caroline Helwick
VBCR - June 2015, Volume 4, No 3
in
Ankylosing Spondylitis
Patients with Myeloma Satisfied with Their Care but Feel Unprepared to Discuss Treatment Choices
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Treatment of Smoldering Myeloma Improves Survival
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Socioeconomics/Demographic Disparities Influence Myeloma Treatment and Survival Outcomes
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Panobinostat, an HDAC Inhibitor, Tested in Combination Regimens for Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Delaying Transplant in Patients with Newly Diagnosed Multiple Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Multiple Myeloma a Hot Topic at ASH 2014
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Multiple Myeloma Studies a High Priority at ASH 2014 Annual Meeting
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Monoclonal Antibodies Poised to Be “Blockbuster Drugs” in Myeloma Management
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
How I Treat Multiple Myeloma in 2014: A Conversation with Sergio A. Giralt, MD
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Encouraging Results for Panobinostat from PANORAMA1: A Phase 3 Clinical Trial
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Adding Lenalidomide to R-CHOP Regimen Delivers a Punch to Diffuse Large B-Cell Lymphoma Subtype
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
ASCO 2014 Highlights: Novel Drug Classes Make News in Multiple Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Management of Patients with Newly Diagnosed Multiple Myeloma Highlighted at ASCO 2014
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
New Dementia Quality Measures Issued by 5 Professional Organizations
Caroline Helwick
VBCN - April 2014 Volume 1, No 1
in
Alzheimer’s Disease/Dementia
Growing Understanding of Genetic Causes of Progressive Myoclonic Epilepsies Improves the Diagnostic Workup
Caroline Helwick
VBCN - April 2014 Volume 1, No 1
in
Personalized Medicine in Neurology
AAN Updated Its Guidelines for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
Caroline Helwick
VBCN - April 2014 Volume 1, No 1
in
Stroke
Value Shown for Alternating Regimens in Elderly Patients with Newly Diagnosed Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Genetic Heterogeneity of Multiple Myeloma Must Be Considered in Treatment Decisions
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Novel Proteasome Inhibitor and HDAC Inhibitor for Myeloma Shine at ASH 2013
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Continuous Use of Lenalidomide Focus of Studies Presented at ASH 2013
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Multiple Myeloma Research Foundation CoMMpass Trial Will Be Clinician-Friendly
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Community Oncology Care Improves Outcomes, Adds Value in the New Models of Cancer Care
Caroline Helwick
VBCC - November 2013, Volume 4, No 9
in
AVBCC 2013 3rd Annual Conference
Give Bisphosphonates to All Newly Diagnosed Patients with Myeloma, Experts Suggest
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
MMRF’s Landmark Study CoMMpass Poised to Uncover the Biology of Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Recent Surveys Highlight Ongoing Challenges for Oncology Practices
Caroline Helwick
VBCC - November 2013, Volume 4, No 9
in
AVBCC 2013 3rd Annual Conference
Growing Pressures on Oncolytics to Demonstrate Value
Caroline Helwick
VBCC - October 2013, Volume 4, No 8
in
AVBCC 2013 3rd Annual Conference
Community Oncology Practices Trying to Keep Afloat
Caroline Helwick
VBCC - October 2013, Volume 4, No 8
in
AVBCC 2013 3rd Annual Conference
Seeking Value in Oncology Care
Caroline Helwick
VBCC - October 2013, Volume 4, No 8
in
AVBCC 2013 3rd Annual Conference
Contracting in the Current Oncology Landscape
Caroline Helwick
VBCC - October 2013, Volume 4, No 8
in
AVBCC 2013 3rd Annual Conference
Addressing Medication Nonadherence: A Patient–Provider Perspective
Caroline Helwick
VBCC - October 2013, Volume 4, No 8
in
AVBCC 2013 3rd Annual Conference
Patient Assistance Programs
Caroline Helwick
VBCC - October 2013, Volume 4, No 8
in
AVBCC 2013 3rd Annual Conference
Pomalidomide plus Low-Dose Dexamethasone Oral Regimen Improves Survival in Relapsed/Refractory Myeloma: Updated Analysis of the MM-003 Trial
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Multiple Myeloma Drug Pipeline Is Full of Novelty
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Implications of the Healthcare Exchanges for Oncology
Caroline Helwick
VBCC - September 2013, Volume 4, No 7
in
AVBCC 2013 3rd Annual Conference
NCCN/National Business Group on Health Collaboration Produces Guide for Employers
Caroline Helwick
VBCC - September 2013, Volume 4, No 7
in
AVBCC 2013 3rd Annual Conference
Defining the Role of Government in Future Oncology Care
Caroline Helwick
VBCC - September 2013, Volume 4, No 7
in
AVBCC 2013 3rd Annual Conference
Bracing for Change in Healthcare Coverage with Medicaid Expansion: What This Means for Cancer Care Delivery
Caroline Helwick
VBCC - September 2013, Volume 4, No 7
in
AVBCC 2013 3rd Annual Conference
Balancing Cost and Quality in Oncology
Caroline Helwick
VBCC - September 2013, Volume 4, No 7
in
Economics of Cancer Care
Quality Measures, Pricing, and Policy Challenges in the Oncology Landscape
Caroline Helwick
VBCC - September 2013, Volume 4, No 7
in
Economics of Cancer Care
Routine Surveillance CT Costly, Unnecessary in Lymphoma in Remission
Caroline Helwick
VBCC - September 2013, Volume 4, No 7
in
Economics of Cancer Care
Should Patients with High-Risk Smoldering Myeloma Undergo Treatment?
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Advances in Multiple Myeloma on the Horizon: An Expert’s View
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Can We Afford to Make Progress in Cancer Care? The Economics of Drug Development
Caroline Helwick
VBCC - July 2013, Volume 4, No 6
in
Economics of Cancer Care
Assessing the Value of New, Costly Radiation Therapies in Older Patients with Breast Cancer
Caroline Helwick
VBCC - July 2013, Volume 4, No 6
in
Economics of Cancer Care
Adenoma Detection Rates in Colonoscopy: The Higher the Better
Caroline Helwick
VBCC - July 2013, Volume 4, No 6
in
Colorectal Cancer
CVS Caremark Value Proposition for Oncology Pharmacy
Caroline Helwick
VBCC - July 2013, Volume 4, No 6
in
AVBCC 2013 3rd Annual Conference
Payers Must Step Up Their Utilization Management Programs
Caroline Helwick
VBCC - July 2013, Volume 4, No 6
in
AVBCC 2013 3rd Annual Conference
A PBM Perspective on Biosimilars
Caroline Helwick
VBCC - July 2013, Volume 4, No 6
in
AVBCC 2013 3rd Annual Conference
Healthcare Reform and End-of-Life Care Myths versus Reality
Caroline Helwick
VBCC - July 2013, Volume 4, No 6
in
AVBCC 2013 3rd Annual Conference
Patient Navigators Enhance Colonoscopy Screening Rates and Save Money in the Long Run
Caroline Helwick
VBCC - July 2013, Volume 4, No 6
in
Patient Navigation
Off-Label Drug Use in Oncology Accounts for 18% of Spending
Caroline Helwick
VBCC - June 2013, Volume 4, No 5
in
Economics of Cancer Care
Cancer Rehabilitation: The Next Frontier in the Care Continuum
Caroline Helwick
VBCC - July 2013, Volume 4, No 6
in
AVBCC 2013 3rd Annual Conference
How Employers Are Adapting to the New Landscape in Healthcare
Caroline Helwick
VBCC - July 2013, Volume 4, No 6
in
AVBCC 2013 3rd Annual Conference
Patient-Centered Oncology Medical Home in New Mexico Demonstrating Value
Caroline Helwick
VBCC - June 2013, Volume 4, No 5
in
AVBCC 2013 3rd Annual Conference
Genomic Sequencing Assay Potentially a Game Changer
Caroline Helwick
VBCC - June 2013, Volume 4, No 5
in
AVBCC 2013 3rd Annual Conference
The Cost of Cancer Care: We Must Incorporate Value and Quality of Life into the Mix
Caroline Helwick
VBCC - June 2013, Volume 4, No 5
in
AVBCC 2013 3rd Annual Conference
Oncology Practices Need to Transform the Way They Deliver Cancer Care
Caroline Helwick
VBCC - June 2013, Volume 4, No 5
in
AVBCC 2013 3rd Annual Conference
The Changing Landscape of Oncology
Caroline Helwick
VBCC - June 2013, Volume 4, No 5
in
AVBCC 2013 3rd Annual Conference
FDA Expected to Approve Surrogate End Point for Neoadjuvant Breast Cancer Trials
Caroline Helwick
VBCC - June 2013, Volume 4, No 5
in
ASCO Annual Meeting
New Analysis Confirms Overall Survival Benefit with Pomalidomide plus Low-Dose Dexamethasone
Caroline Helwick
VBCM - Meeting Highlights
in
ASCO 2013
MLN9708 (Ixazomib) Active as a Single Agent in Relapsed or Refractory Patients
Caroline Helwick
VBCM - Meeting Highlights
in
ASCO 2013
ASCO 2013: Hot Topics in Multiple Myeloma
Caroline Helwick
VBCM - Meeting Highlights
in
ASCO 2013
FDA Expected to Approve Surrogate End Point for Neoadjuvant Breast Cancer Trials
Caroline Helwick
VBCC - News
Low Rates of Peripheral Neuropathy Documented with Carfilzomib
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
For Myeloma Relapse, Re-Treatment with Bortezomib Is Considerably Cost-Saving
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Onyx 360: Not Your Average Patient Assistance Program
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
AVBCC Third Annual Conference: Stakeholders Unite Around Common Challenges
Caroline Helwick
VBCC - May 2013, Volume 4, No 4
in
AVBCC Annual Conference
For Florida Congresswoman with a History of Cancer, Genetic Patent Case Is Personal
Caroline Helwick
VBCC - May 2013, Volume 4, No 4
in
AVBCC Annual Conference
ASCO Urging Oncologists to Consider Value in Patient Care
Caroline Helwick
VBCC - May 2013, Volume 4, No 4
in
AVBCC 2013 3rd Annual Conference
WellPoint’s Perspective on Value-Based Cancer Care for Today and Tomorrow
Caroline Helwick
VBCC - May 2013, Volume 4, No 4
in
AVBCC 2013 3rd Annual Conference
Aetna’s Value-Based Process Improvement for the Survival of Community Oncology
Caroline Helwick
VBCC - May 2013, Volume 4, No 4
in
AVBCC 2013 3rd Annual Conference
Cancer Support Program Documents Savings
Caroline Helwick
VBCC - May 2013, Volume 4, No 4
in
Economics of Cancer Care
Health IT Facilitates Patient Engagement Across Many Settings
Caroline Helwick
VBCC - May 2013, Volume 4, No 4
in
Practice Management
NCCN Update on Multiple Myeloma Therapies
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Novel Assay Identifies Carfilzomib-Resistant Cells in Patients with Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Healthcare of Tomorrow: Digital, Genomic, and Patient-Focused
Caroline Helwick
VBCC - March 2013, Volume 4, No 3
in
Health Policy
Ochsner CEO Calls for Adding Value in Healthcare
Caroline Helwick
VBCC - March 2013, Volume 4, No 3
in
Health Policy
Gabriel N. Hortobagyi, MD, Delivers the William I. McGuire Memorial Lecture
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Chemotherapy
“Chemo Brain” May Be Present Before Chemotherapy
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Chemotherapy
One Year of Trastuzumab Remains the Standard of Care
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Breast Cancer
HER2 Mutations May Become New Treatment Targets
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Breast Cancer
Eribulin Plus Trastuzumab an Effective Combination
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Breast Cancer
Molecular Profiling in Early Invasive Breast Cancer
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Prognostic Tests
Black Women Less Likely to Receive Sentinel Node Dissection Therapy
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Sentinel Node Management
Benefit of Higher Doses of Fulvestrant Confirmed
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Hormone Therapy
HDAC Inhibitor plus PARP Inhibitor or Cisplatin Induce Apoptosis of Triple-Negative Breast Cancer Cells
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Breast Cancer
Venlafaxine Lowers Endoxifen Levels, Reduces Tamoxifen Effectiveness
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Clinical Research
More Evidence Links Vitamin D Deficiency to Worse Outcomes in Breast Cancer
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Clinical Research
Evidence Still Cloudy for Anticancer Effects with Metformin
Caroline Helwick
VBCC - March 2013 - San Antonio Breast Cancer Symposium 2012 Highlights
in
Clinical Research
Gene-Expression Profiling May Help Select Best Drugs for Pancreatic Cancer
Caroline Helwick
VBCC - February 2013, Volume 4, No 2
in
GI Cancers Symposium
In Patients with Colon Cancer, Genomic Classifiers Aid in Prognosis
Caroline Helwick
VBCC - February 2013, Volume 4, No 2
in
GI Cancers Symposium
Mayo Clinic Researchers Propose Screening Algorithm for HER2 in Patients with Esophageal Cancer
Caroline Helwick
VBCC - February 2013, Volume 4, No 2
in
GI Cancers Symposium
Costs of Second-Line Metastatic Colorectal Cancer Treatments Compared
Caroline Helwick
VBCC - February 2013, Volume 4, No 2
in
Health Economics
Most Women Not Willing to Pay for Genetic Breast Cancer Testing
Caroline Helwick
VBCC - February 2013, Volume 4, No 2
in
Health Economics
Second-Line Rituximab Maintenance for Follicular Lymphoma Cost-Effective
Caroline Helwick
VBCC - February 2013, Volume 4, No 2
in
ASH Annual Meeting
Drugs to Reduce Breast Cancer Risk Are Rarely Used Show Data from Geisinger Health System
Caroline Helwick
VBCC - February 2013, Volume 4, No 2
in
Breast Cancer
Novel KSP Inhibitor ARRY-520 Active in Highly Refractory Population
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Using the “New Biology” of Multiple Myeloma to Inform Treatment
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Rasburicase Cost-Effective for Tumor Lysis Syndrome
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
ASH Annual Meeting
Oral Proteasome Inhibitor MLN9708 a News Maker at ASH 2012
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
ASH Annual Meeting
New Data Demonstrate Overall Survival Benefit with Pomalidomide in Advanced Myeloma
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
ASH Annual Meeting
Rivaroxaban More Cost-Effective than Warfarin in the Prevention of Recurrent VTE
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
ASH Annual Meeting
Applying Whole-Genome Analysis to Treatment Decisions in Daily Practice
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
Personalized Medicine
Azacitidine Reduces Transfusions and Costs for Patients with High-Risk MDS
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
Health Economics
Azacitidine Reduces Transfusions and Costs for Patients with High-Risk MDS
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
Health Economics
Multidisciplinary Palliative Care Team at Johns Hopkins Achieves Reduction in ICU Utilization, Cost
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
ASCO’s 1st Quality Care Symposium
Real-Time Performance Tracking Improves Patient Care at 64 Cancer Centers
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
ASCO’s 1st Quality Care Symposium
Cost of Screening Mammography Varies by Strategy
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
Health Economics
Quality Oncology Practice Initiative Shows Strong Improvement in Some Care Measures
Caroline Helwick
VBCC - January 2013, Volume 4, No 1
in
ASCO’s 1st Quality Care Symposium
New Data Demonstrate Overall Survival Benefit with Pomalidomide in Advanced Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Oral Proteasome Inhibitor MLN9708 a News Maker at ASH 2012
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Delta Air Lines’ Approach to Patient Care: High-Performance Cancer Networks
Caroline Helwick
VBCC - November 2012, Volume 3, No 8
in
AVBCC Annual Conference
Cumulative Financial Impact of Skeletal-Related Events on Patients with Breast Cancer Is Significant
Caroline Helwick
VBCC - November 2012, Volume 3, No 8
in
Economics of Cancer Care
The Missing Perspective in Personalized Cancer Care
Caroline Helwick
VBCC - November 2012, Volume 3, No 8
in
Personalized Medicine
Some Staging Studies Not Beneficial in Early Breast Cancer Work-Up
Caroline Helwick
VBCC - November 2012, Volume 3, No 8
in
Breast Cancer Symposium
Employers’ Challenge: Cut Healthcare Costs Without Limiting Employees’ Benefits
Caroline Helwick
VBCC - November 2012, Volume 3, No 8
in
AVBCC Annual Conference
To Many Employers, Specialty Pharmacy Is a Vague Concept
Caroline Helwick
VBCC - November 2012, Volume 3, No 8
in
AVBCC Annual Conference
Cost-Effectiveness Comparison of First-Line Therapies for Advanced Non–Small-Cell Lung Cancer
Caroline Helwick
VBCC - November 2012, Volume 3, No 8
in
ESMO 2012 Conference
Oral Proteasome Inhibitor MLN9708 Evaluated as Novel Therapy for Primary Amyloidosis
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Pomalidomide Demonstrates Overall Survival Benefit in a Phase 3 Clinical Trial
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Health Plans Need Policies for Dealing with Off-Label Drug Use
Caroline Helwick
VBCC - October 2012, Volume 3, No 7
in
AVBCC Annual Conference
Companion Drug Testing Is Becoming Critical to Pharmacy Benefits Management
Caroline Helwick
VBCC - October 2012, Volume 3, No 7
in
AVBCC Annual Conference
Treatment for Myeloma Should Seek to Overcome Genetic Transformations, Dr Anderson Suggests
Caroline Helwick
Value-Based Care in Myeloma
in
Maintenance Therapy
,
Multiple Myeloma
Experimental Compound Effective Against Drug-Resistant Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Front-line Therapy
,
Multiple Myeloma
Recent Study Addresses Surveillance after ASCT
Caroline Helwick
Value-Based Care in Myeloma
in
Relapsed/Refractory
,
Multiple Myeloma
Many Emerging Biomarkers, but Few Are Clinically Applicable
Caroline Helwick
VBCC - October 2012, Volume 3, No 7
in
AVBCC Annual Conference
Indirect Costs of Metastatic Breast Cancer Are Substantial
Caroline Helwick
VBCC - October 2012, Volume 3, No 7
in
Breast Cancer Symposium
Head-to-Head Comparison: Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Caroline Helwick
VBCC - October 2012, Volume 3, No 7
in
ESMO 2012 Conference
Continuation of Bevacizumab Beyond Progression Improves Outcome in Patients with Metastatic Colorectal Cancer
Caroline Helwick
VBCC - October 2012, Volume 3, No 7
in
ESMO 2012 Conference
ESMO Theme: Personalized (“Precision”) Oncology Care Marches Forward
Caroline Helwick
VBCC - October 2012, Volume 3, No 7
in
Personalized Medicine
Is Personalized Cancer Care Affordable?
Caroline Helwick
VBCC - October 2012, Volume 3, No 7
in
Personalized Medicine
An Underappreciated Cause of Cancer Death: Disparities in Treatment
Caroline Helwick
VBCC - October 2012, Volume 3, No 7
in
Breast Cancer Symposium
Relationship between Inflammatory Markers and Symptom Burden in Multiple Myeloma Uncovered
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Landmark Myeloma Study Should Advance Personalized Treatment for Patients
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
NCCN Updates Its Clinical Practice Guidelines for Multiple Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Two Recent Studies Delve Into the Issue of Secondary Cancer Risk
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Induction and Maintenance with Bortezomib Improve Patient Outcomes
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
New Monoclonal Antibodies Show Promise in Patients with Multiple Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Transplant in Multiple Myeloma: Can Some Eligible Patients Avoid It? Interview with Jonathan L. Kaufman, MD
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
“User-Friendly” RVD Schedule Produces High Response Rates
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Defining the Roles of Patient Navigation Can Remove Barriers to Quality Care
Caroline Helwick
VBCC - July 2012, Volume 3, No 5
in
AVBCC Annual Conference
Endocrine Therapy Substantially Underutilized Among Low-Income Patients with Breast Cancer
Caroline Helwick
VBCC - July 2012, Volume 3, No 5
in
ASCO Annual Meeting
Chemotherapy-Related Toxicity Adds to Economic Burden in Metastatic Breast Cancer
Caroline Helwick
VBCC - July 2012, Volume 3, No 5
in
ASCO Annual Meeting
Evidence-Based Guidelines/Pathways Critical for Value-Based Benefit Design in Oncology
Caroline Helwick
VBCC - July 2012, Volume 3, No 5
in
AVBCC Annual Conference
Involving the Patient in End-of-Life Care Decisions: Aetna’s Oncology Strategy
Caroline Helwick
VBCC - July 2012, Volume 3, No 5
in
AVBCC Annual Conference
Tough Times for Small Oncology Practices
Caroline Helwick
VBCC - July 2012, Volume 3, No 5
in
AVBCC Annual Conference
Pathways Offer Providers a True Value Proposition
Caroline Helwick
VBCC - July 2012, Volume 3, No 5
in
AVBCC Annual Conference
Vemurafenib Does Not Impact Health Plan Budget
Caroline Helwick
VBCC - July 2012, Volume 3, No 5
in
AMCP Annual Meeting
In Colorectal Cancer, Treatment Efficacy Is High Among the Elderly
Caroline Helwick
VBCC - July 2012, Volume 3, No 5
in
AMCP Annual Meeting
Pomalidomide Shows Strong Activity in Relapsed/Refractory Myeloma
Caroline Helwick
VBCM - Meeting Highlights
in
ASCO 2012
Maximizing Treatment Benefits with Subcutaneous Bortezomib
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
New Data Show Improved PFS with Lenalidomide Maintenance but OS Results Are Mixed
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Treating Peripheral Neuropathy in Multiple Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Subcutaneous Bortezomib Improves Clinic Efficiency and Patient Satisfaction
Caroline Helwick
VBCM - Meeting Highlights
in
ASCO 2012
MLN9708, First Oral Proteasome Inhibitor, Active in Myeloma
Caroline Helwick
VBCM - Meeting Highlights
in
ASCO 2012
Upfront Therapy for Myeloma: Tailoring Treatment across the Disease Spectrum
Caroline Helwick
VBCM - Meeting Highlights
in
ASCO 2012
Carfilzomib Combinations Should Be Compared with Subcutaneous Bortezomib for Proper Perspective on Neuropathy
Caroline Helwick
VBCM - Meeting Highlights
in
ASCO 2012
The Value of Level I Pathways at US Oncology
Caroline Helwick
VBCC - June 2012, Volume 3, No 4
in
AVBCC Annual Conference
Personalized Medicine Empowers Treatment Decisions
Caroline Helwick
VBCC - June 2012, Volume 3, No 4
in
AVBCC Annual Conference
CareFirst Oncology Management Program Aims to Manage the “Entire Oncology Patient”
Caroline Helwick
VBCC - June 2012, Volume 3, No 4
in
AVBCC Annual Conference
“Precision Medicine” the Theme of ASCO 2012
Caroline Helwick
VBCC - June 2012, Volume 3, No 4
in
ASCO Annual Meeting
Guidelines for Molecular/Cytogenetic Tests Can Eliminate Overordering, Reduce Costs
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
WellPoint: Aligning Reimbursement with Value-Based, Patient-Centered Outcomes
Caroline Helwick
VBCC - May 2012, Volume 3, No 3
in
AVBCC Annual Conference
Community Oncology in Crisis
Caroline Helwick
VBCC - May 2012, Volume 3, No 3
in
AVBCC Annual Conference
Payer Trends in Oncology: Challenges and Solutions
Caroline Helwick
VBCC - May 2012, Volume 3, No 3
in
AVBCC Annual Conference
Seeking Value in Oncology Is Like Chasing an Elephant
Caroline Helwick
VBCC - May 2012, Volume 3, No 3
in
AVBCC Annual Conference
Bone Growth Documented with Bortezomib Treatment
Caroline Helwick
Value-Based Care in Myeloma
in
Bone Health
,
Multiple Myeloma
Evolving Strategies for Cost-Effective Management of Multiple Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Three Induction Regimens Prove Comparable for Elderly, Transplant-Ineligible Patients with Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Delaying Transplant after Immunomodulatory Therapy Does Not Worsen Outcomes
Caroline Helwick
Value-Based Care in Myeloma
in
Transplant Considerations
,
Multiple Myeloma
Early Data for New Akt Inhibitor Show Promise in Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Clinical Trials
,
Multiple Myeloma
Myeloma Update from the NCCN 2012 Annual Conference
Caroline Helwick
VBCM - Meeting Highlights
in
Meeting Highlights
Exploring the Psychosocial Needs of Patients with Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
Meta-Analysis Confirms Benefit of Bortezomib in Induction Regimens before Transplant
Caroline Helwick
Value-Based Care in Myeloma
in
Clinical Trials
,
Multiple Myeloma
Myeloma Update from the NCCN 2012 Annual Conference
Caroline Helwick
VBCM - Meeting Highlights
in
Meeting Highlights
Dose-Dense Chemotherapy plus Growth Factors in Elderly ER-Positive Patients Unnecessary, Costly
Caroline Helwick
VBCC - March 2012, Volume 3, No 2
in
Breast Cancer
For Pancreatic Cancer, Neoadjuvant Chemoradiation Cost-Effective Compared with Surgery First
Caroline Helwick
VBCC - March 2012, Volume 3, No 2
in
Gasterol Intestinal Symposium
Economic Burden of Febrile Neutropenia in NHL Exceeds $11,000 per Episode
Caroline Helwick
VBCC - March 2012, Volume 3, No 2
in
ASH Annual Meeting
Novel Oral B-Cell Receptor Inhibitor Very Effective in Chronic Lymphocytic Leukemia
Caroline Helwick
VBCC - March 2012, Volume 3, No 2
in
ASH Annual Meeting
Confusion Still Surrounds Prophylaxis for Venous Thromboembolism
Caroline Helwick
VBCC - March 2012, Volume 3, No 2
in
ASH Annual Meeting
High-Risk Myelodysplastic Syndrome: First-Line Treatment Choices Often Not Supported by Evidence
Caroline Helwick
VBCC - March 2012, Volume 3, No 2
in
ASH Annual Meeting
For Metastatic Breast Cancer, Nab-Paclitaxel Requires Less Growth Factor Support
Caroline Helwick
VBCC - March 2012, Volume 3, No 2
in
Breast Cancer
Everolimus Has Minimal Economic Impact on Treatment of Pancreatic NETs
Caroline Helwick
VBCC - March 2012, Volume 3, No 2
in
Gasterol Intestinal Symposium
AMA Delegates and Oncologists Balk at ICD-10 Implementation
Caroline Helwick
VBCC - March 2012, Volume 3, No 2
in
Health Policy
HDAC Inhibitors Show Promise in Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
,
Drug Updates
HDAC Inhibitors on the Treatment Horizon
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
,
Drug Updates
New Evidence Confirms Benefit of Antiviral Prophylaxis during Bortezomib Treatment
Caroline Helwick
Value-Based Care in Myeloma
in
Front-line Therapy
,
Multiple Myeloma
What Predicts Early Mortality in Myeloma?
Caroline Helwick
Value-Based Care in Myeloma
in
Front-line Therapy
,
Maintenance Therapy
,
Multiple Myeloma
Physician-Led Approach Can Cut Unnecessary Testing in Prostate Cancer
Caroline Helwick
VBCC - February 2012, Volume 3, No 1
in
Prostate Cancer
Regorafenib Extends Survival in Advanced CRC
Caroline Helwick
VBCC - February 2012, Volume 3, No 1
in
Meeting Highlights
Guidelines for Molecular/Cytogenetic Tests Can Eliminate Overordering, Reduce Costs
Caroline Helwick
VBCC - February 2012, Volume 3, No 1
in
ASH Annual Meeting
A Large Study Sheds Light on the Cost of Managing NHL
Caroline Helwick
VBCC - February 2012, Volume 3, No 1
in
ASH Annual Meeting
Next-Generation Proteasome Inhibitors Cause Less Peripheral Neuropathy
Caroline Helwick
VBCC - February 2012, Volume 3, No 1
in
ASH Annual Meeting
VTE Prophylaxis during Chemotherapy Cost-Effective
Caroline Helwick
VBCC - February 2012, Volume 3, No 1
in
ASH Annual Meeting
Direct-to-Consumer Genetic Testing: Concerns Trump Benefits at This Point
Caroline Helwick
VBCC - February 2012, Volume 3, No 1
in
Health Policy
The Cost of Cancer Care: How Can We Spend Better?
Caroline Helwick
VBCC - February 2012, Volume 3, No 1
in
Breast Cancer
The Promise of Molecular Profiling
Caroline Helwick
VBCC - February 2012, Volume 3, No 1
in
VBCC Perspectives
Future Directions in Myeloma
Caroline Helwick
VBCC - February 2012, Volume 3, No 1
in
Meeting Highlights
Survival Increasing in Patients with Myeloma, but Racial/Ethnic Disparities Continue
Caroline Helwick
Value-Based Care in Myeloma
in
Maintenance Therapy
,
Multiple Myeloma
What Is the Standard of Care for Transplant in Myeloma in 2012?
Caroline Helwick
,
Caroline Helwick
Value-Based Care in Myeloma
in
Transplant Considerations
,
Transplant Considerations
,
Multiple Myeloma
Maintenance Strategies in Elderly Patients with Myeloma Not Eligible for Transplant
Caroline Helwick
,
Caroline Helwick
Value-Based Care in Myeloma
in
Maintenance Therapy
,
Maintenance Therapy
,
Multiple Myeloma
Mechanism of Action of Immunomodulators in Multiple Myeloma Is Being Unraveled
Caroline Helwick
,
Caroline Helwick
Value-Based Care in Myeloma
in
Multiple Myeloma
,
Drug Updates
Pomalidomide Shows an Impressive 42% Clinical Benefit in Relapsed/Refractory Myeloma
Caroline Helwick
Value-Based Care in Myeloma
in
Relapsed/Refractory
,
Clinical Trials
,
Multiple Myeloma
First Oral Proteasome Inhibitor for Multiple Myeloma: Strong Response Activity, Little Neuropathy
Caroline Helwick
VBCM - Meeting Highlights
in
ASH 2011
,
Side Effect Management
,
Clinical Trials
AMA Calls for More Transparency in Patient Navigation Programs
Caroline Helwick
VBCC - December 2011, Volume 2, No 7
in
Patient Navigation
Economic Implications of Biosimilars in Oncology
Caroline Helwick
VBCC - December 2011, Volume 2, No 7
in
Drug Updates
Dual HER2 Blockade with Pertuzumab Substantially Delays Disease Progression
Caroline Helwick
VBCC - December 2011, Volume 2, No 7
in
CTRC-AACR SABCS Annual Meeting
Adding Everolimus to Exemestane Significantly Prolongs Remission in Patients with Breast Cancer
Caroline Helwick
VBCC - December 2011, Volume 2, No 7
in
CTRC-AACR SABCS Annual Meeting
New Prognostic Tool to Guide Treatment of Ductal Carcinoma In Situ
Caroline Helwick
VBCC - December 2011, Volume 2, No 7
in
CTRC-AACR SABCS Annual Meeting
SWOG: Two Hormonal Agents Extend Survival over Anastrozole Alone in Metastatic Breast Cancer
Caroline Helwick
VBCC - December 2011, Volume 2, No 7
in
CTRC-AACR SABCS Annual Meeting
Medical Staff Members Spend Many Hours Dealing with Insurance Companies
Caroline Helwick
VBCC - December 2011, Volume 2, No 7
in
Health Policy
Thromboembolism after Chemotherapy Raises Healthcare Costs about 30%
Caroline Helwick
VBCC - December 2011, Volume 2, No 7
in
ESMO 2011 Conference
Delivering Affordable, Evidence-Based Cancer Care in High-Income Countries
Caroline Helwick
VBCC - December 2011, Volume 2, No 7
in
ESMO 2011 Conference
Young Patients Are Served Equally Well by Lumpectomy or Mastectomy
Caroline Helwick
VBCC - December 2011, Volume 2, No 7
in
ASCO Breast Cancer Symposium
Therapy-Associated Complications Significantly Increase Cost of Cancer Care
Caroline Helwick
VBCC - October 2011, Volume 2, No 6
in
ESMO 2011 Conference
New Bone-Targeting Compound Improves Survival in Metastatic Prostate Cancer
Caroline Helwick
VBCC - October 2011, Volume 2, No 6
in
ESMO 2011 Conference
Pemetrexed Plus Bevacizumab Maintenance Keeps NSCLC at Bay Longer
Caroline Helwick
VBCC - October 2011, Volume 2, No 6
in
ESMO 2011 Conference
Value of Bevacizumab in Ovarian Cancer Got a Boost in a New Analysis
Caroline Helwick
VBCC - October 2011, Volume 2, No 6
in
ESMO 2011 Conference
Positive Data Continue to Accrue for Crizotinib in ALK-Positive NSCLC
Caroline Helwick
VBCC - October 2011, Volume 2, No 6
in
ESMO 2011 Conference
Everolimus-Exemestane Combination Prolongs Remission by 4 Months in Metastatic Breast Cancer
Caroline Helwick
VBCC - October 2011, Volume 2, No 6
in
ESMO 2011 Conference
New T-DM1 Reduces Disease Progression by 40% in Advanced Breast Cancer, with Low Toxicity
Caroline Helwick
VBCC - October 2011, Volume 2, No 6
in
ESMO 2011 Conference
Targeted Radiation Therapy Gaining Momentum
Caroline Helwick
VBCC - October 2011, Volume 2, No 6
in
Breast Cancer Symposium
Survivorship Programs an Emerging Need, But Are They Cost-Effective?
Caroline Helwick
VBCC - October 2011, Volume 2, No 6
in
Survivorship Care
Patients with Cancer at Risk for Bankruptcy
Caroline Helwick
VBCC - August 2011, Volume 2, No 5
in
ASCO Annual Meeting
Genome-Forward Medicine in Lung Cancer
Caroline Helwick
VBCC - August 2011, Volume 2, No 5
in
ASCO Annual Meeting
Comparing the Value of Denosumab versus Zoledronic Acid in Preventing Cancer-Related Skeletal Events
Caroline Helwick
VBCC - August 2011, Volume 2, No 5
in
ASCO Annual Meeting
Accountable Care Organizations: Implications for Cancer-Related Quality Care and Spending
Caroline Helwick
VBCC - August 2011, Volume 2, No 5
in
Health Policy
Dose-Monitoring, Split-Fill Programs Reduce Oral Chemotherapy Waste, Save Costs
Caroline Helwick
VBCC - August 2011, Volume 2, No 5
in
Oncology
Post-ASCO Survey: Oncologists’ and Payers’ Treatment and Coverage Decisions
Caroline Helwick
VBCC - August 2011, Volume 2, No 5
in
Reimbursement
Screening for Pancreatic Cancer Is Effective, Has Value— at Least in High-Risk Individuals
Caroline Helwick
VBCC - August 2011, Volume 2, No 5
in
Cancer Care
Colonoscopy Overused in Medicare Recipients, Adding Unnecessary Expenditures
Caroline Helwick
VBCC - August 2011, Volume 2, No 5
in
Cancer Care
Significant Advances in Lung Cancer Highlighted at AACR
Caroline Helwick
VBCC - June 2011, Volume 2, No 3
in
AACR Annual Meeting
Competing Tests for Colorectal Cancer Risk Recurrence
Caroline Helwick
VBCC - April 2011, Volume 2, No 2
in
Genitourinary Cancers Symposium
Future of Colorectal Cancer Therapy: Novel Targeted Pathways
Caroline Helwick
VBCC - April 2011, Volume 2, No 2
in
Genitourinary Cancers Symposium
Hypertension a Good Sign in Patients Receiving Sunitinib
Caroline Helwick
VBCC - April 2011, Volume 2, No 2
in
Genitourinary Cancers Symposium
Sorafenib Active Third-Line in Refractory GIST
Caroline Helwick
VBCC - April 2011, Volume 2, No 2
in
Genitourinary Cancers Symposium
Staying Afloat in Stormy Waters
Caroline Helwick
VBCC - Other
High Copays Associated with Discontinuation of Hormonal Breast Cancer Therapy
Caroline Helwick
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
Combination Anti-HER2 Therapies the Wave of the Future
Caroline Helwick
VBCC - February 2011, Volume 2, No 1
in
Meeting Highlights
High Copays Associated with More Discontinuations of Hormonal Breast Cancer Therapy
Caroline Helwick
VBCC - Other
in
SABCS 2014
Future Anti-HER2 Therapy Likely to be Costly
Caroline Helwick
VBCC - Other
Contralateral Prophylactic Mastectomy Improves Survival, Is Cost-Effective in Some
Caroline Helwick
VBCC - November/December 2010, Volume 1, No 6
in
ASCO Breast Cancer Symposium
High Cost to Managing Colorectal Cancer Toxicities
Caroline Helwick
VBCC - November/December 2010, Volume 1, No 6
in
ESMO 2010 Conference
Cancer Drugs: NICE Rejects Costly Treatments
Caroline Helwick
VBCC - November/December 2010, Volume 1, No 6
in
Cancer Care
Some Biologics Fail in Early-Stage Tumors
Caroline Helwick
VBCC - November/December 2010, Volume 1, No 6
in
Colon Cancer
Hematopoietic Growth Factors: What’s New in 2010?
Caroline Helwick
VBCC - Other
Last modified: May 19, 2010
Home
Issues
2018
April 2018, Vol 7, No 1
2017
December 2017, Vol 6, No 5
October 2017, Vol 6, No 4
August 2017, Vol 6, No 3
June 2017, Vol 6, No 2
April 2017, Vol 6, No 1
2016
December 2016, Vol 5, No 6
October 2016, Vol 5, No 5
August 2016, Vol 5, No 4
June 2016, Vol 5, No 3
April 2016, Vol 5, No 2
February 2016, Vol 5, No 1
Issues Archive
Supplements
Categories
Web Exclusives
All Web Exclusives
FDA Approvals, News & Updates
In The News
Online First
Videos
About
About VBCR
About Engage HC
Contact Us
Editorial/Publishing Policies
Editorial Board
Advertising Contacts
Advertising Policy
Author Guidelines